The Pacific Northwest Udall Center (PANUC) is a collaborative enterprise among physicians and scientists at Oregon Health &Science University and the University of Washington that focuses considerable experience and expertise on cognitive impairment, a relatively poorly understood but devastating consequence that is common in patients afflicted with Parkinson's disease (PD). This proposed new Udall Center would be the only one in Oregon or the WWAMl region;WWAMI is an acronym for the cooperative arrangement among states in Pacific Northwest for which the University of Washington is the only medical school and academic medical center: Washington, Wyoming, Alaska, Montana, and Idaho. Thus, PANUC would cOver an area greater than one-fourth of the entire U.S.A. where more than 13 million Americans live. PANUC will achieve several goals of the NIH and NINDS. PANUC is: eminently patient-oriented, focused on a common non-motor feature of PD that is relatively poorly understood, organized into highly inter-related cores and projects that will promote exchange of new knowledge among clinical, translational, and basic research, anxious to contribute fully to the PD Data Organizing Center (PD-DOC) and the Coriell Institute for submission to the NINDS Human Genefics Repository, and composed of investigators who have a longstanding track record of highly collaborative productivity despite being at two institutions. Our mission is twofold. First, PANUC will serve PD patients, along with their caregivers and health care providers. We will provide improved education and clinical care, as well as offer new opportunities to participate in clinical research. Second, PANUC will discover and investigate the mechanisms that underlie cognitive impairment in PD using an array of cutting-edge technologies from accomplished and collaborative laboratories, generating novel resources for the community of scientists focused on PD, and identifying potential targets for future therapeutic development.
PANUC has a three-fold mission: (i) Serve patients with Parkinson disease (PD), along with their caregivers and health care providers, (ii) Investigate and elucidate mechanisms that underlie cognitive impairment (Cl) in PD using an array of cutting-edge technologies from accomplished laboratories, identifying targets for future therapeutic development, and (iii) Create new knowledge and generate novel resources for clinical, translational, and basic research to be shared with the community of scientists investigating Cl in PD.
|Flanagan, Margaret E; Cholerton, Brenna; Latimer, Caitlin S et al. (2018) TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study. J Alzheimers Dis 66:1549-1558|
|Gray, Shelly L; Anderson, Melissa L; Hanlon, Joseph T et al. (2018) Exposure to Strong Anticholinergic Medications and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort. J Alzheimers Dis 65:607-616|
|Moreno, Monica A; Or-Geva, Noga; Aftab, Blake T et al. (2018) Molecular signature of Epstein-Barr virus infection in MS brain lesions. Neurol Neuroimmunol Neuroinflamm 5:e466|
|Condello, Carlo; Lemmin, Thomas; Stöhr, Jan et al. (2018) Structural heterogeneity and intersubject variability of A? in familial and sporadic Alzheimer's disease. Proc Natl Acad Sci U S A 115:E782-E791|
|Locke, Timothy M; Soden, Marta E; Miller, Samara M et al. (2018) Dopamine D1 Receptor-Positive Neurons in the Lateral Nucleus of the Cerebellum Contribute to Cognitive Behavior. Biol Psychiatry 84:401-412|
|Cholerton, Brenna; Johnson, Catherine O; Fish, Brian et al. (2018) Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. Parkinsonism Relat Disord 50:29-36|
|Blue, Elizabeth E; Bis, Joshua C; Dorschner, Michael O et al. (2018) Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer's Disease Sequencing Project. Dement Geriatr Cogn Disord 45:1-17|
|Houser, Madelyn C; Chang, Jianjun; Factor, Stewart A et al. (2018) Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease. Mov Disord 33:793-804|
|Wile, Daryl J; Agarwal, Pankaj A; Schulzer, Michael et al. (2017) Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Lancet Neurol 16:351-359|
|Dublin, Sascha; Walker, Rod L; Gray, Shelly L et al. (2017) Use of Analgesics (Opioids and Nonsteroidal Anti-Inflammatory Drugs) and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort. J Alzheimers Dis 58:435-448|
Showing the most recent 10 out of 178 publications